Search
Novo Nordisk Launches Clinical Trial for Next-Generation Weight Loss Therapy Tailored for Chinese Population
2025-08-15 /
Read about 0 minute
Author：小编
Novo Nordisk has recently embarked on a Phase I clinical trial in China, aimed at assessing the safety, tolerability, and pharmacokinetic properties of a novel drug, NNC0487-0111, specifically in individuals who are overweight or obese. This randomized, double-blind study intends to enroll 36 Chinese participants with a Body Mass Index (BMI) ranging from 24 to 34.9 over a duration of 53 days. The trial is poised to deliver vital insights, paving the way for the development of effective obesity treatment options tailored to the Chinese population.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
